Cryo-shocked cancer cells for targeted drug delivery and vaccination

Ci, Tianyuan; Li, Hong Jun; Chen, Guojun; Wang, Zejun; Wang, Jinqiang; Abdou, Peter; Tu, Yiming; Dotti, Gianpietro; Gu, Zhen

doi:10.1126/sciadv.abc3013

Cited by 103 publications

(74 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, Ci et al. [ 193 ] used liquid nitrogen to prepare dead acute myeloid leukemia (AML) cells and constructed drug delivery vehicles that encapsulated Dox. Due to the fact that dead cells have similar protein expression as the source cells, dead cells kept their bone marrow homing capability of live AML cells.…”

Section: Future Perspectivesmentioning

confidence: 99%

The role of non‐coding RNAs in drug resistance of oral squamous cell carcinoma and therapeutic potential

Meng¹,

Lou

Yang³

et al. 2021

Cancer Communications

View full text Add to dashboard Cite

Oral squamous cell carcinoma (OSCC), the eighth most prevalent cancer in the world, arises from the interaction of multiple factors including tobacco, alcohol consumption, and betel quid. Chemotherapeutic agents such as cisplatin, 5‐fluorouracil, and paclitaxel have now become the first‐line options for OSCC patients. Nevertheless, most OSCC patients eventually acquire drug resistance, leading to poor prognosis. With the discovery and identification of non‐coding RNAs (ncRNAs), the functions of dysregulated ncRNAs in OSCC development and drug resistance are gradually being widely recognized. The mechanisms of drug resistance of OSCC are intricate and involve drug efflux, epithelial‐mesenchymal transition, DNA damage repair, and autophagy. At present, strategies to explore the reversal of drug resistance of OSCC need to be urgently developed. Nano‐delivery and self‐cellular drug delivery platforms are considered as effective strategies to overcome drug resistance due to their tumor targeting, controlled release, and consistent pharmacokinetic profiles. In particular, the combined application of new technologies (including CRISPR systems) opened up new horizons for the treatment of drug resistance of OSCC. Hence, this review explored emerging regulatory functions of ncRNAs in drug resistance of OSCC, elucidated multiple ncRNA‐meditated mechanisms of drug resistance of OSCC, and discussed the potential value of drug delivery platforms using nanoparticles and self‐cells as carriers in drug resistance of OSCC.

show abstract

Section: Future Perspectivesmentioning

confidence: 99%

The role of non‐coding RNAs in drug resistance of oral squamous cell carcinoma and therapeutic potential

Meng¹,

Lou

Yang³

et al. 2021

Cancer Communications

View full text Add to dashboard Cite

show abstract

“…An important benefit common to the tumor ablation therapies is breaking the immunotolerance of the host to the treated tumor orchestrated by local thermal, oxidative or electric stress [5,6]. Temperature stress (hot or cold) is induced by treatments like microwave ablation, radiofrequency ablation, photothermal therapy (PTT), cryoablation therapy (CAT), and high frequency ultrasound [3].…”

Section: Tumor Ablation Therapies and Antitumor Immunitymentioning

confidence: 99%

Novel Immune Stimulant Amplifies Direct Tumoricidal Effect of Cancer Ablation Therapies and Their Systemic Antitumor Immune Efficacy

Korbelik¹,

Hode

Lam

et al. 2021

Cells

View full text Add to dashboard Cite

Ablation therapies have emerged as an effective tool for destroying cancerous tissue, but for advanced and disseminated tumors their application remains mainly a palliative measure. However, it is becoming increasingly clear that this limitation can be redressed by the use of intratumoral immune stimulating agents for amplifying potential antitumor immune responses that are induced by ablation therapies. A novel immune stimulating drug IP-001, a specific variant of the N-dihydrogalactochitosan (GC) family of molecules, has shown to be effective against metastatic tumors, when combined with different forms tumor ablation. It acts as a multi-function immune stimulant both by directly inhibiting cell membrane repair and recycling of ablation-damaged tumor cells, and indirectly by sequestering ablation-released tumor antigens, as well as recruiting and stimulating antigen presenting cells to induce a potent Th1 type T cell response against the cancer. In this review, we briefly discuss the current applications of local ablation for cancer treatment and the effects of GC in combination with other ablation therapies, a therapeutic approach that is pioneering the field of Interventional Immuno-Oncology (IIO).

show abstract

“…Currently, combined therapies targeting LSCs mobilization from protective shelters have been tested under various phases of clinical trials. In addition, cell-mediated drug-delivery system facilitating the targeted transport of chemotherapeutic agents provides a new insight to improve the efficacy of current chemotherapy regimens, although it has not been confirmed by clinical trials [ 123 ]. Here we summarize current available strategies targeting BMM that might represent potential directions for future adjunctive therapeutics (Table 1 , Fig.…”

Section: Strategies Targeting Bmm In Amlmentioning

confidence: 99%

Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development

Yao

Huang

et al. 2021

Exp Hematol Oncol

View full text Add to dashboard Cite

Despite the advances in intensive chemotherapy regimens and targeted therapies, overall survival (OS) of acute myeloid leukemia (AML) remains unfavorable due to inevitable chemotherapy resistance and high relapse rate, which mainly caused by the persistence existence of leukemia stem cells (LSCs). Bone marrow microenvironment (BMM), the home of hematopoiesis, has been considered to play a crucial role in both hematopoiesis and leukemogenesis. When interrupted by the AML cells, a malignant BMM formed and thus provided a refuge for LSCs and protecting them from the cytotoxic effects of chemotherapy. In this review, we summarized the alterations in the bidirectional interplay between hematopoietic cells and BMM in the normal/AML hematopoietic environment, and pointed out the key role of these alterations in pathogenesis and chemotherapy resistance of AML. Finally, we focused on the current potential BMM-targeted strategies together with future prospects and challenges. Accordingly, while further research is necessary to elucidate the underlying mechanisms behind LSC–BMM interaction, targeting the interaction is perceived as a potential therapeutic strategy to eradicate LSCs and ultimately improve the outcome of AML.

show abstract

Cryo-shocked cancer cells for targeted drug delivery and vaccination

Cited by 103 publications

References 38 publications

The role of non‐coding RNAs in drug resistance of oral squamous cell carcinoma and therapeutic potential

The role of non‐coding RNAs in drug resistance of oral squamous cell carcinoma and therapeutic potential

Novel Immune Stimulant Amplifies Direct Tumoricidal Effect of Cancer Ablation Therapies and Their Systemic Antitumor Immune Efficacy

Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development

Contact Info

Product

Resources

About